Obsidio
Payments companies reported to CMS as associated with Obsidio. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Obsidio, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Obsidio
These are the largest totals companies reported as associated with Obsidio. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Juan Gimenez | New Orleans, LA | Vascular & Interventional Radiology | $27,567.33 |
| Kevin Henseler | Roseville, MN | Diagnostic Radiology | $12,065.82 |
| Abhishek Kumar | Philadelphia, PA | Vascular & Interventional Radiology | $10,426.49 |
| Rahmi Oklu | Scottsdale, AZ | Vascular & Interventional Radiology | $10,244.15 |
| Vivian Bishay | New York, NY | Vascular & Interventional Radiology | $8,702.73 |
| Guy Johnson | Seattle, WA | Diagnostic Radiology | $8,537.34 |
| Joshua Kuban | Houston, TX | Vascular & Interventional Radiology | $8,117.29 |
| Mikin Patel | Chicago, IL | Diagnostic Radiology | $8,022.37 |
| Dania Daye | Framingham, MA | Vascular & Interventional Radiology | $6,863.62 |
| Anuj Malhotra | Albany, NY | Vascular & Interventional Radiology | $3,836.03 |
Prescribed Obsidio?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.